Literature DB >> 15938028

Treatment of high-risk patients with diabetes: motivation and teaching intervention: a randomized, prospective 8-year follow-up study.

Rita Rachmani1, Inna Slavacheski, Maya Berla, Ronni Frommer-Shapira, Mordchai Ravid.   

Abstract

The aim of this study was to examine whether motivating patients to gain expertise and closely follow their risk parameters will attenuate the course of microvascular and cardiovascular sequelae of diabetes. A randomized, prospective study was conducted of 165 patients who had type 2 diabetes, hypertension, and hyperlipidemia and were referred for consultation to a diabetes clinic in an academic hospital. Patients were randomly allocated to standard consultation (SC) or to a patient participation (PP) program. Both groups were followed by their primary care physicians. The mean follow-up was 7.7 yr. The SC group attended eight annual consultations. The PP patients initiated on average one additional consultation per year. There were 80 cardiovascular events (eight deaths) in the SC group versus 47 events (five deaths) in the PP group (P = 0.001). The relative risk (RR) over 8 yr for a cardiovascular event in the intervention (PP) versus the control (SC) group was 0.65 (95% confidence interval, 0.89 to 0.41). There were 17 and eight cases of stroke in the SC and PP groups, respectively (P = 0.05). RR for stroke was 0.47 (95% confidence interval, 0.85 to 0.32). In the SC group, 14 patients developed overt nephropathy (four ESRD) versus seven (one ESRD) in the PP group (P = 0.05). Throughout the study period, BP, LDL cholesterol, and hemoglobin A1c were significantly lower in the PP than in the SC patients. Well informed and motivated patients were more successful in obtaining and maintaining good control of their risk factors, resulting in reduced cardiovascular risk and slower progression of microvascular disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15938028     DOI: 10.1681/asn.2004110965

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  13 in total

Review 1.  Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Nat Rev Rheumatol       Date:  2015-02-17       Impact factor: 20.543

Review 2.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

Review 3.  Effectiveness and safety of patient activation interventions for adults with type 2 diabetes: systematic review, meta-analysis, and meta-regression.

Authors:  Shari D Bolen; Apoorva Chandar; Corinna Falck-Ytter; Carl Tyler; Adam T Perzynski; Alida M Gertz; Paulette Sage; Steven Lewis; Maurine Cobabe; Ying Ye; Michelle Menegay; Donna M Windish
Journal:  J Gen Intern Med       Date:  2014-04-15       Impact factor: 5.128

4.  Diabetes self-management education: miles to go.

Authors:  Helen Altman Klein; Sarah M Jackson; Kenley Street; James C Whitacre; Gary Klein
Journal:  Nurs Res Pract       Date:  2013-03-20

5.  Treating rheumatoid arthritis to target: recommendations of an international task force.

Authors:  Josef S Smolen; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maarten de Wit; Maxime Dougados; Paul Emery; Alan Gibofsky; Juan Jesus Gomez-Reino; Boulos Haraoui; Joachim Kalden; Edward C Keystone; Tore K Kvien; Iain McInnes; Emilio Martin-Mola; Carlomaurizio Montecucco; Monika Schoels; Désirée van der Heijde; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-03-09       Impact factor: 19.103

6.  Translating patient education theory into practice: developing material to address the cardiovascular education needs of people with rheumatoid arthritis.

Authors:  Holly John; Elizabeth D Hale; Paul Bennett; Gareth J Treharne; Douglas Carroll; George D Kitas
Journal:  Patient Educ Couns       Date:  2010-07-17

7.  Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire.

Authors:  Boulos Haraoui; Josef S Smolen; Daniel Aletaha; Ferdinand C Breedveld; Gerd Burmester; Catalin Codreanu; José Pereira Da Silva; Maarten de Wit; Maxime Dougados; Patrick Durez; Paul Emery; João Eurico Fonseca; Allan Gibofsky; Juan Gomez-Reino; Winfried Graninger; Vedat Hamuryudan; Maria José Jannaut Peña; Joachim Kalden; Tore K Kvien; Ieda Laurindo; Emilio Martin-Mola; Carlomaurizio Montecucco; Pedro Santos Moreno; Karel Pavelka; Gyula Poor; Mario H Cardiel; Ewa Stanislawska-Biernat; Tsutomu Takeuchi; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2011-07-29       Impact factor: 19.103

8.  Predictors of quality of life of patients with type 2 diabetes.

Authors:  Ruth Kalda; Anneli Rätsep; Margus Lember
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

9.  The effect of a patient-oriented treatment decision aid for risk factor management in patients with diabetes (PORTDA-diab): study protocol for a randomised controlled trial.

Authors:  Petra Denig; Mathijs Dun; Jan Schuling; Flora M Haaijer-Ruskamp; Jaco Voorham
Journal:  Trials       Date:  2012-11-21       Impact factor: 2.279

10.  Strategies for establishing policy, environmental, and systems-level interventions for managing high blood pressure and high cholesterol in health care settings: a qualitative case study.

Authors:  Dyann Matson Koffman; Sharon A Granade; Victoria V Anwuri
Journal:  Prev Chronic Dis       Date:  2008-06-15       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.